Several companies have announced their intention to produce COVID-19 vaccines in Africa. Across Africa, competences related to earlier stages of the value chain are very limited. Indian companies have developed pharma competences, especially in generic medicines and vaccines, and benefit from a large domestic market. Given all these constraints, a potential new plant in Africa would not be operational in 2021, and would not help solve the immediate need for vaccines now. Yet, vaccine building vaccine competences is a goal with longer-term benefits.

Source: The North Africa Journal June 23, 2021 15:33 UTC